REFERENCES
- Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462.
- Mann J, Ritz E. Preservation of kidney function by use of converting enzyme inhibitors for control of hyper-tension. Lancet 1987; 2: 622.
- Maschio G, Alberti D, Janin G, LocateIli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-convert-ing-enzyme inhibition in progressive renal insufficiency study group. N Engl J Med 1996; 11,334: 939–945.
- Parving 1111, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by capto-pril in insulin dependent diabetics with nephropathy. Br Med J 1988; 297: 1086–1091.
- Mann J, Reisch C, Ritz E. Use of angiotensin enzyme inhibitors for the preservation of kidney function. Nephron 1990; 55: 38–42.
- Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term effect of angiotensin converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetes patients. Ann Intern Med 1993; 118: 577–581.
- Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of thera-peutic selection. Kidney Int 1992; 41: 912–919.
- Berivet F, Poulot D, Dormont J. Reversible acute renal failure during enalapril treatment in patients with chronic renal failure with and without renal artery-stenosis. Lancet 1985; i: 1512.
- van den Meiracker AH, Man Veld AJ, Admiraal PJ, Ritsema van Eck HJ, Boomsma F, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive effects? J Hypertens 1992; 10: 803–812.
- Stefanski A, Amann K, Ritz E. To prevent progression. ACE inhibitors, calcium channel blockers or both? Nephrol Dial Transplant 1995; 10: 151–153.
- Duarte CG, Elvebach LR, Leidtke RR In: Duarte CG, editor. Renal function tests. Glomerular filtration rate and renal plasma flow. Boston: Little Brown, 1986: 29–47.
- Hannedouche T, Delgado A, Gnionsahe A, Lacour B, Grunfeld JP. Influence of nicardipine on renal hemody-namics and segmental tubular reabsorption of sodium in humans. J Cardiovasc Parmacol 1989; 14: 856-861. Erman A, Van Dyk DJ, Chen Gal B, Giler ID, Rosenfeld JB, Boner G. Angiotensin converting enzyme activity in the serum, lung and kidney of diabetic rats. Eur J Clin Invest 1993; 23: 615–620.
- Erman A, Van Dyk DJ, Chen Gal B, Giler ID, Rosenfeld JB, Boner G. Angiotensin converting enzyme activity in the serum, lung and kidney of diabetic rats. Eur J Clin Invest 1993; 23: 615�620.
- Natov S, Hannedouche T, Schmitt F, Ikeni A, Dechaux M, Kirkisseli S. Are the renal hemodynamic and natriuretic effects of calcium antagonists and converting enzyme inhibitors additive? J Hypertens 1991; 6 Suppl 9: 392–393.
- Reams GP, Lau A, Knaus V. Short and long term effects of spirapril on renal hemodynamics in patients with essential hypertension. J Clin Pharmacol 1993; 33: 348–353.
- Kostis JB. Angiotensin converting enzyme inhibitors. II. Clinical use. Am Heart J 1988; 116: 1591–1605.
- Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar M. Single-drug therapy for hypertension in men. N Engl J Med 1993; 328: 914–921.
- Gavras H, Gavras I, Textor S, Volicer L, Brunner HR, Rucinska EJ. Effect of converting enzyme inhibition on blood pressure, plasma renin activity and plasma aldo-sterone in essential hypertension. J Clin Endocrinol Metab 1978; 46: 220–226.